L A Sumerel

1.1k total citations
10 papers, 919 citations indexed

About

L A Sumerel is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, L A Sumerel has authored 10 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Genetics. Recurrent topics in L A Sumerel's work include Virus-based gene therapy research (4 papers), RNA Interference and Gene Delivery (4 papers) and CAR-T cell therapy research (3 papers). L A Sumerel is often cited by papers focused on Virus-based gene therapy research (4 papers), RNA Interference and Gene Delivery (4 papers) and CAR-T cell therapy research (3 papers). L A Sumerel collaborates with scholars based in United States and France. L A Sumerel's co-authors include David T. Curiel, Albert F. LoBuglio, Joanne T. Douglas, R M Conry, M. Wright, Delicia Carey, D L Barlow, Frosty Loechel, Susan E. Moore and Richard J. Benjamin and has published in prestigious journals such as Nucleic Acids Research, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

L A Sumerel

9 papers receiving 885 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L A Sumerel United States	9	657	489	323	316	128	10	919
Nikolay Korokhov United States	16	474 0.7×	512 1.0×	214 0.7×	294 0.9×	119 0.9×	26	829
Murielle Gantzer France	8	544 0.8×	620 1.3×	209 0.6×	400 1.3×	127 1.0×	13	915
Parameshwar J. Mahasreshti United States	19	633 1.0×	647 1.3×	139 0.4×	448 1.4×	73 0.6×	20	1.0k
Taco G. Uil Netherlands	17	606 0.9×	628 1.3×	60 0.2×	334 1.1×	147 1.1×	21	839
Derek Ostertag United States	11	341 0.5×	259 0.5×	325 1.0×	252 0.8×	58 0.5×	35	736
Xinping Fu United States	19	490 0.7×	664 1.4×	171 0.5×	478 1.5×	204 1.6×	32	1.0k
Daphné Benteyn Belgium	13	664 1.0×	196 0.4×	791 2.4×	463 1.5×	77 0.6×	19	1.1k
Christine E. Engeland Germany	18	385 0.6×	792 1.6×	257 0.8×	674 2.1×	178 1.4×	38	1.1k
Hanna Dreja United Kingdom	13	399 0.6×	197 0.4×	438 1.4×	143 0.5×	103 0.8×	24	818
Sarah Godbehere United States	15	319 0.5×	299 0.6×	394 1.2×	173 0.5×	179 1.4×	33	848

Countries citing papers authored by L A Sumerel

Since Specialization

Citations

This map shows the geographic impact of L A Sumerel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L A Sumerel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L A Sumerel more than expected).

Fields of papers citing papers by L A Sumerel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L A Sumerel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L A Sumerel. The network helps show where L A Sumerel may publish in the future.

Co-authorship network of co-authors of L A Sumerel

This figure shows the co-authorship network connecting the top 25 collaborators of L A Sumerel. A scholar is included among the top collaborators of L A Sumerel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L A Sumerel. L A Sumerel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Kim, Myung‐Hee, Thomas M. Bodenstine, L A Sumerel, et al.. (2006). Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo. Cancer Biology & Therapy. 5(12). 1647–1653. 8 indexed citations

2.

Sumerel, L A, et al.. (2003). The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. British Journal of Cancer. 88(9). 1411–1416. 71 indexed citations

3.

Zinn, Kurt R., Brian Barnett, L A Sumerel, et al.. (2002). The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. European Journal of Cancer. 38(14). 1917–1926. 118 indexed citations

4.

Douglas, Joanne T., et al.. (2001). Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors.. PubMed. 61(3). 813–7. 145 indexed citations

5.

Conry, Robert M., Albert F. LoBuglio, Frosty Loechel, et al.. (1995). A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity.. PubMed. 2(1). 59–65. 95 indexed citations

6.

Conry, R M, et al.. (1995). A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expressionin vivo. Nucleic Acids Research. 23(9). 1495–1501. 80 indexed citations

7.

Conry, R M, Albert F. LoBuglio, Frosty Loechel, et al.. (1995). A carcinoembryonic antigen polynucleotide vaccine for human clinical use.. PubMed. 2(1). 33–8. 52 indexed citations

8.

Conry, R M, Albert F. LoBuglio, M. Wright, et al.. (1995). Characterization of a messenger RNA polynucleotide vaccine vector.. PubMed. 55(7). 1397–400. 253 indexed citations

9.

Conry, R M, Albert F. LoBuglio, Judy Kantor, et al.. (1994). Immune response to a carcinoembryonic antigen polynucleotide vaccine.. PubMed. 54(5). 1164–8. 96 indexed citations

10.

Conry, Robert M., et al.. (1993). An animal model to predict the immunogenicity of murine V regions in humans. Human Antibodies. 4(4). 174–180. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact